Vaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing its 31-valent pneumococcal conjugate ...

The CDC revised its pneumococcal pneumonia shot recommendation, saying there is a substantial increase in the risk for infection beginning at age 50.

Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD. Just-reported ...

Antimicrobial resistance and serotypes in Streptococcus pneumoniae have been evolving with the widespread use of antibiotics and the introduction of pneumococcal conjugate vaccines (PCV).

Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data -- -- Company Expects to ...

The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive ...

Beginning at a very young age, babies are vaccinated to prevent more than a dozen serious diseases, and failure to vaccinate ...

Vaxcyte (PCVX) announced that the first study participants have been dosed in the second and final stage of the ongoing Phase 2 study of VAX-31 ...

Medicare Advantage plans, sometimes called Part C, also cover the pneumonia vaccine. Pneumococcal vaccines can prevent common bacterial infections from Streptococcus pneumoniae. There are two ...

Beginning at a very young age, babies are vaccinated to prevent more than a dozen serious diseases, and failure to vaccinate ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Advisory Committee on Immunization Practices (ACIP) has lowered the recommended age for pneumococcal vaccination from 65 to ...